<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01467362</url>
  </required_header>
  <id_info>
    <org_study_id>V00034 CR 3 12 1B</org_study_id>
    <secondary_id>2011-003295-37</secondary_id>
    <nct_id>NCT01467362</nct_id>
  </id_info>
  <brief_title>Efficacy Emollient on Xerosis in Children With Atopic Dermatitis</brief_title>
  <official_title>Efficacy of the V0034CR01B Emollient on Xerosis in Children With Atopic Dermatitis. Randomised, Vehicle-controlled, Parallel-groups, Double-blind Study With an Open Label Extension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atopic dermatitis is a frequent, chronic inflammatory disease influenced by local,
      immunological, genetic and environmental factors. Important symptoms of atopic dermatitis are
      dry skin, intense pruritus and impaired epidermal barrier function. Atopic dermatitis is
      associated with skin barrier dysfunction that facilitates an easier allergen penetration into
      the skin with an increased irritation and subsequent cutaneous inflammation. A lack of
      important stratum corneum intercellular lipids and an inadequate ratio between compounds
      enhance trans-epidermal water loss leading to xerosis. Skin hydration by emollient therapy
      usually twice daily improves dryness and subsequently pruritus during the treatment of atopic
      dermatitis and especially improves the barrier function. Emollients make part of basic
      therapy (grade 1) for treatment of atopic dermatitis (European Academy of Dermatology and
      Venereology Task Force 2009 Position Paper). Improvement of cutaneous barrier alteration,
      measured by skin hydration, is a key element for evaluation of emollient treatment efficacy.

      The primary objective of this study is to demonstrate the efficacy of the tested product
      (V0034CR01B) cream on xerosis in children with atopic dermatitis compared to the excipient
      formula during 28 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Xerosis score: mean evolution over the different time-points of double-blind period</measure>
    <time_frame>During 28 days (Day 1, Day 7, Day 14, Day 21 and Day 28)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hydration Index score : measurement of the skin hydration</measure>
    <time_frame>Day 1, Day 14, Day 28, Day 56 and Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Xerosis score evolution over the different time-ponts during open label period</measure>
    <time_frame>At Visit1 (Day 1) and at Day 56 and Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Xerosis Visual Analogue Scale (evaluation skin dryness)</measure>
    <time_frame>Day 1, Day 14, Day 28, Day 56 and Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scoring for Atopic Dermatitis (SCORAD) : measurement of objective symptoms of Atopic Dermatitis.</measure>
    <time_frame>Day1, Day 28, Day 56 and Day 84.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall assessment of treatment efficacy by the investigator</measure>
    <time_frame>Day 28 and Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall assessment of treatment efficacy and use by the parent(s)/guardian(s)</measure>
    <time_frame>at Day 28 and at Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the local tolerability and the systemic safety (reported adverse events)</measure>
    <time_frame>Day 1, Day 7, Day 14, Day 21, Day 28, Day 56 and Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Topical corticosteroid assessment</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28, Day 56 and Day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>V0034CR01B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V0034CR01B</intervention_name>
    <description>Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days</description>
    <arm_group_label>V0034CR01B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle cream</intervention_name>
    <description>Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days</description>
    <arm_group_label>Vehicle cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desonide 0.1% cream</intervention_name>
    <description>cream, once a day (in the evening) during flares</description>
    <arm_group_label>V0034CR01B</arm_group_label>
    <arm_group_label>Vehicle cream</arm_group_label>
    <other_name>Locapred</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Foaming gel</intervention_name>
    <description>for the washing and cleaning</description>
    <arm_group_label>V0034CR01B</arm_group_label>
    <arm_group_label>Vehicle cream</arm_group_label>
    <other_name>Pediatril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presenting with atopic dermatitis, dry skin, objective SCORAD &lt; 15,

          -  With xerosis on the body and a xerosis score &gt; = 2 (SCORAD sub-score) on the anterior
             part of lower limbs,

        Exclusion Criteria:

          -  Acute phase of atopic dermatitis

          -  Severe form of atopic dermatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck BORALEVI, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Estonia</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Estonia</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>France</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>France</name>
      <address>
        <city>Martigues</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>France</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>France</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>France</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lithuania</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poland</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poland</name>
      <address>
        <city>Inowrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poland</name>
      <address>
        <city>Oleśnica</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poland</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poland</name>
      <address>
        <city>Płock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poland</name>
      <address>
        <city>Strzelce Opolskie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poland</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poland</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poland</name>
      <address>
        <city>Żyrardów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Romania</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Romania</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Romania</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Romania</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Romania</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Romania</name>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Romania</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Romania</name>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>France</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>November 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <last_update_submitted>February 20, 2013</last_update_submitted>
  <last_update_submitted_qc>February 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>xerosis</keyword>
  <keyword>dry skin</keyword>
  <keyword>dermatitis</keyword>
  <keyword>pruritus</keyword>
  <keyword>eczema</keyword>
  <keyword>emollient</keyword>
  <keyword>corticosteroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emollients</mesh_term>
    <mesh_term>Desonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

